C. Marco Timmers - Concepedia

Author

C. Marco Timmers

Also Known As

C M Timmers, C Marco Timmers, C. M. TIMMERS, C. M. Timmers, C. Marco Timmers, C.M. Timmers, Cornelis M Timmers, Cornelis M. Timmers, Cornelis Timmers, Cornelis M. Timmers

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Leiden University MSD (Netherlands)Merck & Co., Inc., Rahway, NJ, USA (United States)Merck (Netherlands)SNV Netherlands Development Organisation

About

C. Marco Timmers is an author at Leiden University specializing in pharmacology, medicine, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	779
2	Natural Sciences	12	12	459
3	Biochemistry	12	12	342
4	Engineering	3	3	82
5	Public Health	2	2	74

C. Marco Timmers

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985 Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts, Molecular Pharmaceutics Molecular BiologyDuocarmycin 3BPharmaceutical ChemistryMedicinal ChemistryToward Selection	2015	214
The First Orally Active Low Molecular Weight Agonists for the LH Receptor: Thienopyr(im)idines with Therapeutic Potential for Ovulation Induction Nicole C.R. van Straten, G. G. Schoonus-Gerritsma, R. G. van Someren, ChemBioChem Lh ReceptorTherapeutic PotentialGynecologyPharmacotherapyHigh Molecular Weight	2002	104
A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor Chris J. van Koppen, Guido J.R. Zaman, C. Marco Timmers, Naunyn-Schmiedeberg s Archives of Pharmacology Molecular PharmacologyMolecular PhysiologySignal TransductionBiochemistryG Protein-coupled Receptor	2008	97
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Jonathan Black, Gulden Menderes, Stefania Bellone, Molecular Cancer Therapeutics	2016	91
Identification of Substituted 6-Amino-4-phenyltetrahydroquinoline Derivatives: Potent Antagonists for the Follicle-Stimulating Hormone Receptor Nicole C.R. van Straten, Twan H. J. van Berkel, Dennis Demont, Journal of Medicinal Chemistry	2004	81
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor Ruud van de Lagemaat, C. Marco Timmers, J. Kelder, Human Reproduction	2008	70
Prevention of the Onset of Ovarian Hyperstimulation Syndrome (OHSS) in the Rat After Ovulation Induction with a Low Molecular Weight Agonist of the LH Receptor Compared with hCG and rec-LH Ruud van de Lagemaat, Bianca Raafs, C. van Koppen, Endocrinology FertilityReproductive HealthGynecologyFemale Reproductive FunctionOvarian Aging	2011	52
A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines Ruud G. E. Coumans, G.J.A. Ariaans, Henri Spijker, Bioconjugate Chemistry	2020	52
Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor Chris J. van Koppen, P. M. Verbost, Ruud van de Lagemaat, Biochemical Pharmacology Molecular PharmacologyMolecular PhysiologySignal TransductionG Protein-coupled ReceptorMedicine	2013	51
[3H]Org 43553, the First Low-Molecular-Weight Agonistic and Allosteric Radioligand for the Human Luteinizing Hormone Receptor Laura H. Heitman, Julia Oosterom, Kimberly M. Bonger, Molecular Pharmacology	2007	51

Page 1